Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): Impact on health‐related quality of life

Eichhorst, B., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Yang, K., Wu, K., Salmi, T., Barnes, G., & Brown, J. R. (2023). Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): Impact on health‐related quality of life. Hematological Oncology, 41(S2), 463–464. Portico. https://doi.org/10.1002/hon.3164_341

Authors:

Barbara Eichhorst

Nicole Lamanna

Susan O’Brien

Constantine S. Tam

Lugui Qiu

K. Yang

Kenneth K. Wu

T. Salmi

G. Barnes

Jennifer R. Brown

Affiliated Authors: